title: Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
abstract: Antisense therapy is a powerful tool for inducing post-transcriptional modifications and thereby regulating target genes associated with disease. There are several classes of antisense oligonucleotides (AONs) with therapeutic use, such as double-stranded RNAs (interfering RNAs, utilized for gene silencing, and single-stranded AONs with various chemistries, which are useful for antisense targeting of micro-RNAs and mRNAs. In particular, the use of AONs for exon skipping, by targeting pre-mRNA, is proving to be a highly promising therapy for some genetic disorders like Duchenne muscular dystrophy and spinal muscular atrophy. However, AONs are unable to cross the plasma membrane unaided, and several other obstacles still remain to be overcome, in particular their instability due to their nuclease sensitivity and their lack of tissue specificity. Various drug delivery systems have been explored to improve the bioavailability of nucleic acids, and nanoparticles (NPs) have been suggested as potential vectors for DNA/RNA. This review describes the recent progress in AON conjugation with natural and synthetic delivery systems, and provides an overview of the efficacy of NP-AON complexes as an exon-skipping treatment for Duchenne muscular dystrophy.
authors: 1 Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara , Ferrara, Italy .
authors: Maria Sofia
authors: MS
authors: Falzarano
authors: Chiara
authors: C
authors: Passarelli
authors: Alessandra
authors: A
authors: Ferlini
mesh_terms: D000818:Animals; D004285:Dogs; D016503:Drug Delivery Systems; D016189:Dystrophin / Q000235:genetics; D005091:Exons; D006801:Humans; D008297:Male; D051379:Mice; D018101:Mice, Inbred mdx; D009137:Muscular Dystrophy, Animal / Q000235:genetics / Q000628:therapy; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics* / Q000628:therapy*; D050997:Nanomedicine; D053758:Nanoparticles / Q000008:administration & dosage; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000235:genetics* / Q000627:therapeutic use; D052416:Targeted Gene Repair / Q000379:methods*
chemical_list: C484258:DMD protein, human; D016189:Dystrophin; D016376:Oligonucleotides, Antisense